Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 17/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102056 | 0.86 | P2RX7 (0.48) | P2RX7ALDH1A1PLA2G1BKMT2ANPSR1 | |
| SCHEMBL13995722 | 0.83 | P2RX7 (0.41) | P2RX7ALDH1A1PLA2G1BKMT2ANPSR1 | |
| SCHEMBL13644157 | 0.80 | CYP2D6 (0.44) | P2RX7ALDH1A1PLA2G1BKMT2ANPSR1 | |
| SCHEMBL31136802 | 0.80 | CYP2D6 (0.44) | P2RX7ALDH1A1PLA2G1BKMT2ANPSR1 | |
| SCHEMBL24973959 | 0.79 | NPC1 (0.39) | P2RX7HTR2CSLC6A4ALDH1A1HSD17B10 | |
| SCHEMBL19954188 | 0.79 | HTT (0.45) | P2RX7CYP2D6PKMCYP2C19 | |
| SCHEMBL15055515 | 0.79 | KMT2A (0.51) | P2RX7HTR2CSLC6A4KMT2A | |
| SCHEMBL13995328 | 0.78 | P2RX7 (0.43) | P2RX7 | |
| SCHEMBL19954232 | 0.76 | HTR2C (0.43) | P2RX7HTR2CSLC6A4CYP2D6PKM | |
| SCHEMBL12312605 | 0.76 | P2RX7 (0.44) | P2RX7ALDH1A1KMT2ACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283300-A1 | USE OF BENZO-HETEROCYCLE DERIVATIVES FOR PREVENTING AND TREATING CANCER OR FOR INHIBITING CANCER METASTASIS | SNU R&DB FOUNDATION (KR) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283300-A1 | USE OF BENZO-HETEROCYCLE DERIVATIVES FOR PREVENTING AND TREATING CANCER OR FOR INHIBITING CANCER METASTASIS | MKI67, KISS1R, NPY1R | P2RX7 734/4885HTR2C 3378/4885SLC6A4 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.